Kovecses and colleagues reveal that targeted delivery of small activating RNAs restores CEBPA expression in acute myeloid leukemia, enhancing sensitivity to FLT3 inhibition and reducing leukemic burden. Here, FLT3 is linked to acute myeloid leukemia.